Zydus Cadila slumps 2 per cent despite getting approval for Droxidopa capsules

Zydus Cadila has received USFDA approval to market Droxidopa capsules, which come in the strength of 100 mg, 200 mg & 300 mg.   

The capsule is used to treat patients with low blood pressure that causes severe dizziness or a light-headed feeling. It works on the principle of narrowing or constricting the blood vessels, which thereby increases the blood pressure in the patients. The drug is indicated for use in patients with conditions of the nervous system that can cause low blood pressure (such as Parkinson's disease, multiple system atrophy, autonomic failure, and others).  

The capsule will be manufactured by the company at its formulation manufacturing facility at SEZ, Ahmedabad. Currently, the company has 312 approvals and has so far filed 400 ANDAs since its commencement in the financial year 2003-04.  

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.  

Aurobindo Pharmaceuticals Limited have also recieved USFDA approval for manufacturing and selling of Droxidopa capsules.

At 12.15 pm on Friday, the shares of the Cadila Healthcare were trading at Rs 459.25 per piece on NSE, which is 1.8 per cent down from its previous close of Rs 467.25.